EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Long-term progression-free survival following multimodal therapy for mucinous adenocarcinoma of the appendix: A case report

Sara Filipović, Jovana Trifunović, Miroslav Kreačić, Nemanja Trifunović, Nataša Rakonjac

Taurunum Medical Journal · 2025

DOI: 10.63696/tmj202502189 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Taurunum Medical Journal, 2025. Verfasst von Sara Filipović und 4 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

<p>Introduction: Primary adenocarcinoma of the appendix is a rare and heterogeneous malignancy, most commonly presenting as mucinous adenocarcinoma. Due to its nonspecific clinical manifestations, the diagnosis is often established at an advanced stage, frequently with already present peritoneal dissemination. Standard treatment for advanced mucinous appendiceal carcinoma involves cytoreductive surgery with HIPEC followed by systemic chemotherapy, or initial systemic therapy for downstaging, followed by repeat CRS and HIPEC. In cases where radical surgery is not feasible, the average survival is less than one year. Case report: We report a case of a 72-year-old woman with no relevant family history, who presented with acute right lower abdominal pain and distension. Imaging revealed multiple cystic peritoneal implants, ascites, and small bowel obstruction. Palliative emergency surgery demonstrated an appendiceal mass invading the right ovary, with widespread peritoneal mucinous deposits. Histopathological analysis confirmed mucinous adenocarcinoma of the appendix with peritoneal carcinomatosis. Postoperatively, the patient received 12 cycles of bevacizumab plus FOLFOX chemotherapy, achieving marked radiologic and biochemical improvement. Maintenance therapy with bevacizumab plus 5-FU/LV led to sustained disease stabilization. After 32 cycles, the patient developed an entero-vaginal fistula, which was surgically managed due to poor quality of life. Intraoperatively, the decision was made for cytoreductive surgery and fistulectomy. Postoperative imaging showed no evidence of disease. The patient remains progression-free for nearly three years, and disease-free for one year. Conclusion: This case highlights the potential for long-term survival in initially inoperable patients with advanced mucinous appendiceal adenocarcinoma and peritoneal carcinomatosis when treated with combined cytoreductive surgery and bevacizumab plus chemotherapy. Multimodal and individualized treatment strategies may significantly improve outcomes in this rare malignancy.</p>

Zitieren

APA

Filipović, S., Trifunović, J., Kreačić, M., Trifunović, N., & Rakonjac, N. (2025). Long-term progression-free survival following multimodal therapy for mucinous adenocarcinoma of the appendix: A case report. Taurunum Medical Journal. https://doi.org/10.63696/tmj202502189

Vancouver

Filipović S, Trifunović J, Kreačić M, Trifunović N, Rakonjac N. Long-term progression-free survival following multimodal therapy for mucinous adenocarcinoma of the appendix: A case report. Taurunum Medical Journal. 2025. doi:10.63696/tmj202502189

BibTeX
@article{Filipovi2025,
  author = {Filipović, Sara and Trifunović, Jovana and Kreačić, Miroslav and Trifunović, Nemanja and Rakonjac, Nataša},
  title = {Long-term progression-free survival following multimodal therapy for mucinous adenocarcinoma of the appendix: A case report},
  journal = {Taurunum Medical Journal},
  year = {2025},
  doi = {10.63696/tmj202502189}
}
Kostenlos starten →